一段话概述
Lilly is one of the world's largest pharmaceutical companies. It entered gene editing by buying Verve Therapeutics in 2025 for around a billion dollars, acquiring a programme designed to lower cholesterol permanently with a single treatment — a signal that large pharmaceutical companies now see in vivo editing as a serious commercial proposition rather than a science project.
Eli Lilly and Company acquired Verve Therapeutics in 2025 for approximately $1 billion plus contingent value rights, adding in vivo base editing for cardiovascular disease to a portfolio spanning metabolic, oncology and neuroscience medicines. The transaction is among the clearest indications of large-pharma conviction in the modality.
Sources
- Eli Lilly and Company · 2025
Lilly to acquire Verve Therapeutics ↗
非投资建议
本档案为依据公开披露信息汇编的教育性资料，不构成对任何证券的买入、卖出或持有建议，也不代表对该公司前景的任何判断。生物技术领域具有高度投机性，大多数临床项目最终以失败告终。
完整免责声明 →